 | |
| Image from Actos. com |
In the summer of 2011, the FDA issued a warning regarding
Actos (pioglitazone hydrochloride), a drug used to help individuals with Type 2
diabetes. According to the FDA, medications containing pioglitazone
hydrochloride may increase an individual’s risk of developing bladder cancer,
especially if a patient has used the medication for over a year. Find related FDA updates here.
The Actos-Cancer Link
Physicians in France have stopped prescribing medications
with pioglitazone hydrochloride to patients with diabetes because of a similar
cancer link that researchers found. German physicians have also stopped
prescribing the medication.
According to the FDA, you should not take Actos or
medications containing pioglitazone hydrochloride if you have a history of, or
currently have, bladder cancer. Make sure you tell your doctor if you have a
family or personal history of bladder cancer, or if you develop any of the
following symptoms while taking Actos:
- A red or unusual color, or blood, in your urine
- An urgent need to urinate
- Pain while urinating
- Pain in your lower back or abdomen
Even if you are not taking Actos or do not have diabetes,
you should tell your doctor if you develop any of the aforementioned
symptoms.
Actos Lawsuit
According to Simmons
Law Firm, you may be entitled to compensation if you took Actos and
developed cancer before Takeda Pharmaceuticals changed the drug label. Additional
side effects of Actos, which is in the thiazolidinedione drug class, may also
include an increased risk of:
- Serious, but rare liver problems
- Congestive heart failure (CHF)
- Bone fractures
Learn more about the Actos
lawsuit.
If You Currently Take Actos
To control your Type 2 diabetes symptoms, the FDA recommends
that you use diet and exercise to help control your blood sugar levels. If your
physician has prescribed Actos, do not stop taking your medication until you
have discussed your concerns with your physician.
This post is brought to you by Simmons
Law Firm. All views and opinions expressed are mine.
No comments:
Post a Comment